Compare
Verrica Pharmaceuticals Inc. vs Verastem, Inc. vs Aquestive Therapeutics, Inc. vs Journey Medical Corp
| Latest fiscal year | Verrica Pharmaceuticals Inc. VRCA | Verastem, Inc. VSTM | Aquestive Therapeutics, Inc. AQST | Journey Medical Corp DERM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $35.58M | $30.91M | $44.55M | $61.24M |
| Revenue growth (YoY) | +370.2% | +209.1% | -22.6% | +11.1% |
| Gross margin | n/a | n/a | 58.3% (computed) | 65.8% (computed) |
| Operating margin | -34.2% | -550.3% | -159.5% | -13.3% |
| Net margin | -50.3% | -677.6% | -188.1% | -18.7% |
| Net income | -$17.89M | -$209.47M | -$83.78M | -$11.43M |
| EPS (Diluted) | -$1.68 | -$3.02 | -$0.78 | -$0.47 |
| Operating cash flow | -$17.63M | -$137.51M | -$52.43M | -$12.44M |
| Free cash flow | -$17.63M | n/a | -$52.99M | n/a |
| Cash & equivalents | $30.15M | $204.99M | n/a | $24.09M |
| Total assets | $47.13M | $246.44M | $160.43M | $94.59M |
| Total liabilities | $22.39M | $189.25M | $194.09M | $62.74M |
| Shareholders' equity | $24.74M | $57.20M | -$33.66M | $31.85M |
| Return on year-end equity | -72.3% | -366.2% | n/a | -35.9% |
| Shares outstanding | 17.18M | 77.74M | 122.04M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Verrica Pharmaceuticals Inc. | Verastem, Inc. | Aquestive Therapeutics, Inc. | Journey Medical Corp |
|---|---|---|---|---|
| Latest | $35.58M Ended 2025-12-31 | $30.91M Ended 2025-12-31 | $44.55M Ended 2025-12-31 | $61.24M Ended 2025-12-31 |
| 1 year earlier | $7.57M Ended 2024-12-31 | $10.00M Ended 2024-12-31 | $57.56M Ended 2024-12-31 | $55.13M Ended 2024-12-31 |
| 2 years earlier | $5.12M Ended 2023-12-31 | n/a | $50.58M Ended 2023-12-31 | $59.66M Ended 2023-12-31 |
| 3 years earlier | $9.03M Ended 2022-12-31 | $2.60M Ended 2022-12-31 | $47.68M Ended 2022-12-31 | $71.00M Ended 2022-12-31 |
| 4 years earlier | $12.00M Ended 2021-12-31 | $2.05M Ended 2021-12-31 | $50.83M Ended 2021-12-31 | $63.13M Ended 2021-12-31 |